{
    "clinical_study": {
        "@rank": "1345", 
        "arm_group": [
            {
                "arm_group_label": "Pulse Fibre", 
                "arm_group_type": "Experimental", 
                "description": "The intervention group will receive a biscuit containing 5g/serving of yellow pea fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The placebo group will receive a biscuit an isocaloric control biscuit that is similar in taste and texture and without pulse fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals."
            }
        ], 
        "brief_summary": {
            "textblock": "The recent dramatic increase in obesity has been linked to a reduction of dietary fibre\n      intake. We hypothesized that supplementing the diet of overweight and obesity adults with\n      pulse fibre will improve their metabolic status, chiefly defined as greater weight loss.\n      Other metabolic health improvements may include improved glucose control and reduced\n      inflammatory markers."
        }, 
        "brief_title": "Evaluation of Pulse Fibre Supplementation on Obesity and the Metabolic Syndrome", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Metabolic Syndrome X"
            ]
        }, 
        "detailed_description": {
            "textblock": "The main objective of our study is to assess the effects of pulse fibre supplementation on\n      weight loss in an overweight and obese adult population.\n\n      Primary objective - To determine the effects of a 12 week intake of 15g/day of pea hull\n      fibre on weight loss supported by body composition measures.\n\n      Secondary objective - To measure glucose control and appetite regulation in overweight and\n      obese adults consuming 15g/day of pea hull fibre compared to a placebo control with the use\n      of plasma HbA1c and an oral glucose tolerance test (OGTT)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females\n\n          -  Age 18 - 70 years\n\n          -  BMI 25 - 38 kg/m-2\n\n          -  Stable body weight  for at least 3 months prior to the study\n\n        Exclusion Criteria:\n\n          -  Concomitant use of any weight loss medication, diet or exercise regime\n\n          -  Use of corticosteroids, anti-depressants, anti-epileptic medications, lipid lowering\n             medication, diabetes medications\n\n          -  Previous bariatric or other intestinal surgeries\n\n          -  Pregnancy or lactation\n\n          -  Weight loss > 3 kg within preceding 3 months to enrollment\n\n          -  Use of bulk laxatives or probiotics/prebiotics supplements\n\n          -  Antibiotic use in the past month\n\n          -  Clinically significant cardiovascular or respiratory or liver disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719900", 
            "org_study_id": "24804"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pulse Fibre", 
                "description": "Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.", 
                "intervention_name": "Pulse fibre", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Control biscuit with no yellow pea hull fibre.", 
                "intervention_name": "Control", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dietary intervention", 
            "Dietary fibre", 
            "Obesity", 
            "Metabolic syndrome", 
            "Weight loss", 
            "Glucose regulation", 
            "Pulse fibre"
        ], 
        "lastchanged_date": "May 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Calgary", 
                    "country": "Canada", 
                    "state": "Alberta", 
                    "zip": "T2N 1N4"
                }, 
                "name": "University of Calgary"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of Pulse Fibre Supplementation in Obesity and the Metabolic Syndrome: Generating Evidence in Support of Health Claims", 
        "other_outcome": [
            {
                "measure": "Change in baseline lipid profile at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in baseline inflammatory markers at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessed with dual energy x-ray absorptiometry.", 
            "measure": "Change in baseline fat mass at 12 weeks", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719900"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Calgary", 
            "investigator_full_name": "Dr. Raylene Reimer", 
            "investigator_title": "Professor, Faculty of Kinesiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessed via HbA1c and an oral glucose tolerance test.", 
                "measure": "Change in baseline glucose tolerance at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Subjective appetite assessed with visual analog scales and objective appetite with a weighed lunch buffet.", 
                "measure": "Change in baseline appetite at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "University of Calgary", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Alberta Innovates Health Solutions", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Alberta Innovates - Bio Solutions", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Alberta Pulse Growers Commission", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Calgary", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}